Cell Based Assays Market by Offering (Reagents, Assays Kits, Cell Lines, Microplates, Probes, Labels, Instruments & Software), Technology (Flowcytometry, HTS), Application (Drug Discovery (Toxicity, Pharmacokinetics), Research) - Global Forecast to 2029
The cell-based assays market is projected to reach USD 24.3 billion by 2029 from an estimated USD 17.3 billion in 2024, at a CAGR of 7.1% during the forecast period from 2024 to 2029. The growth of this market can be attributed to the increasing need of drug discovery and growing demand for cell-based assays in drug discovery. The rising R&D investments by pharmaceutical & biotechnology industries is propelling the growth of cell-based assays market. Also, growing incidences of cancer is promoting the need of advanced therapies resulting to boost the growth of cell-based assays market. Moreover, growing applications of cell-based assays in chronic diseases and personalized medicine is expected to propel the market growth in coming years.
“The drug discovery segment accounted for the largest share of by application segment in 2023.”
Based on application, cell-based assays market is segmented into drug discovery, basic research, genetic studies, and other applications. Drug discovery segment is further categories into toxicity studies, pharmacokinetic studies, and pharmacodynamic studies. In 2023, the drug discovery segment accounted for the largest share of the global cell-based assays market by application. Increasing prevalence of cancer is driving the need of advanced thearpies resulting to promote segment's growth in the cell-based assays market. Additionally, increasing R&D investments, the introduction of new drugs, and the growing number of contract research organizations providing drug discovery services to pharmaceutical and biotechnology companies are also expected to drive to promote the segment's growth in cell-based assays market.
“The flow cytometry segment accounted for the major share by technology segment in 2023.”
Based on technology, cell-based assays market is segmented into flow cytometry, high throughput screening, label free detection, and other technologies. In 2023, the flow cytometry segment accounted for the major share of the global cell-based assays market by technology. The growth of the flow cytometry segment is primarily attributed to the wide usage of flow cytometry for cell-based assays to perform multiple measurements. Additionally, growing adoption of advanced technologies for cell analysis and cell characterization is anticipated to boost the segment growth in cell-based assays market.
“The US has continued to dominate the cell-based assays market in 2023.”
Based on the region, the cell-based assays market is segmented into six major regions including North America, Europe, Asia Pacific, Latin America, Middle East, and Africa. In 2023, US dominated the cell-based assays market in North America. The US is the world’s largest biopharmaceutical market and a leader in biopharmaceutical research/investments. The US also has a strong healthcare infrastructure, which drives research and development in the life sciences sector. Additionally, the significant presence of many biopharmaceutical companies and growing research activities in the biotechnology industry are propelling market growth in the US. Moreover, growing focus on development of advanced cell-based therapies due to growing incidences of cancer is also driving the growth of the cell-based assays market.
The primary interviews conducted for this report can be categorized as follows:
This research report categorizes the cell-based assays market by offering (consumables (reagents, assay kits (reporter gene assays, cell growth assays, second messenger assays, cell death assays, and other assay kits), microplates, cell line (immortalized cell lines, primary cell lines, and stem cell lines), probes & labels, and other consumables), instruments, software, and services, technology (flow cytometry, high throughput screening, label-free detection, and other technologies), application (drug discovery (toxicology, pharmacodynamics, and pharmacokinetics), basic research, genetic studies, and other applications), end user (pharmaceutical & biopharmaceutical companies, contract research organizations (CROs), and academic & research institutes), and by region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the cell-based assays market. A thorough analysis of the key industry players has been done to provide insights into their business overview, products, key strategies, collaborations, partnerships, and agreements. Also, it includes new product launches, collaborations and acquisitions, and recent developments associated with the cell-based assays market.
Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing the closest approximations of the revenue numbers for the overall cell-based assays market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to position their business better and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.
The report provides insights on the following pointers:
“The drug discovery segment accounted for the largest share of by application segment in 2023.”
Based on application, cell-based assays market is segmented into drug discovery, basic research, genetic studies, and other applications. Drug discovery segment is further categories into toxicity studies, pharmacokinetic studies, and pharmacodynamic studies. In 2023, the drug discovery segment accounted for the largest share of the global cell-based assays market by application. Increasing prevalence of cancer is driving the need of advanced thearpies resulting to promote segment's growth in the cell-based assays market. Additionally, increasing R&D investments, the introduction of new drugs, and the growing number of contract research organizations providing drug discovery services to pharmaceutical and biotechnology companies are also expected to drive to promote the segment's growth in cell-based assays market.
“The flow cytometry segment accounted for the major share by technology segment in 2023.”
Based on technology, cell-based assays market is segmented into flow cytometry, high throughput screening, label free detection, and other technologies. In 2023, the flow cytometry segment accounted for the major share of the global cell-based assays market by technology. The growth of the flow cytometry segment is primarily attributed to the wide usage of flow cytometry for cell-based assays to perform multiple measurements. Additionally, growing adoption of advanced technologies for cell analysis and cell characterization is anticipated to boost the segment growth in cell-based assays market.
“The US has continued to dominate the cell-based assays market in 2023.”
Based on the region, the cell-based assays market is segmented into six major regions including North America, Europe, Asia Pacific, Latin America, Middle East, and Africa. In 2023, US dominated the cell-based assays market in North America. The US is the world’s largest biopharmaceutical market and a leader in biopharmaceutical research/investments. The US also has a strong healthcare infrastructure, which drives research and development in the life sciences sector. Additionally, the significant presence of many biopharmaceutical companies and growing research activities in the biotechnology industry are propelling market growth in the US. Moreover, growing focus on development of advanced cell-based therapies due to growing incidences of cancer is also driving the growth of the cell-based assays market.
The primary interviews conducted for this report can be categorized as follows:
- By Respondent: Supply Side- 60% and Demand Side 40%
- By Designation: Managers - 45%, CXO & Directors - 30%, and Executives - 25%
- By Region: North America - 40%, Europe -25%, Asia-Pacific -25%, Latin America -5% and Middle East & Africa- 5%
- BD (US)
- Thermo Fisher Scientific Inc. (US)
- Danaher Corporation (US)
- Merck KGaA (Germany)
- Agilent Technologies, Inc. (US)
- Lonza (Switzerland)
- Charles River Laboratories (US)
- Bio-Rad Laboratories, Inc. (US)
- Revvity (US)
- Sartorius AG (Germany)
- Corning Incorporated (US)
- Promega Corporation (US)
- Cell Signaling Technology, Inc. (US)
- Eurofins Scientific (Luxembourg)
- Enzo Biochem, Inc. (US)
- Carna Biosciences, Inc. (Japan)
- Intertek Group plc (UK)
- BICO (Sweden)
- Cell Biolabs, Inc. (US)
- Reaction Biology (US)
- AAT Bioquest, Inc. (US)
- Pestka Biomedical Laboratories, Inc. (US)
- Neuromics (US)
- BPS Bioscience, Inc. (US)
- BellBrook Labs (US)
- Profacgen (US)
- BMG LABTECH (Germany)
- Hanugen Theraputics (India)
- Altogen Labs (US)
- BioAgilytix (US)
This research report categorizes the cell-based assays market by offering (consumables (reagents, assay kits (reporter gene assays, cell growth assays, second messenger assays, cell death assays, and other assay kits), microplates, cell line (immortalized cell lines, primary cell lines, and stem cell lines), probes & labels, and other consumables), instruments, software, and services, technology (flow cytometry, high throughput screening, label-free detection, and other technologies), application (drug discovery (toxicology, pharmacodynamics, and pharmacokinetics), basic research, genetic studies, and other applications), end user (pharmaceutical & biopharmaceutical companies, contract research organizations (CROs), and academic & research institutes), and by region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the cell-based assays market. A thorough analysis of the key industry players has been done to provide insights into their business overview, products, key strategies, collaborations, partnerships, and agreements. Also, it includes new product launches, collaborations and acquisitions, and recent developments associated with the cell-based assays market.
Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing the closest approximations of the revenue numbers for the overall cell-based assays market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to position their business better and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.
The report provides insights on the following pointers:
- Analysis of key drivers (rising demand for drug discovery & development and increasing preference for cell-based assays in drug discovery, surge in cases of cancer, and increasing R&D investments and fundings for cell-based research), restraints (high cost of instruments and restrictions imposed by product end-user licenses for reagents), opportunities (growing applications of cell-based assays in chronic diseases and personalized medicine), and Challenges (complexities in assay designs) influencing the growth of the market.
- Product Development/Innovation: Detailed insights on newly launched products of the cell-based assays market
- Market Development: Comprehensive information about lucrative markets - the report analyses the market across varied regions.
- Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the cell-based assays market
- Competitive Assessment: BD (US), Thermo Fisher Scientific Inc. (US), Danaher Corporation (US), Merck KGaA (Germany), Agilent Technologies, Inc. (US), Lonza (Switzerland), Charles River Laboratories (US), Bio-Rad Laboratories, Inc. (US), Revvity (US), Sartorius AG (Germany), Corning Incorporated (US), Promega Corporation (US), Cell Signaling Technology, Inc. (US), Eurofins Scientific (Luxembourg), Enzo Biochem, Inc. (US), Carna Biosciences, Inc. (Japan), Intertek Group plc (UK), BICO (Sweden), Cell Biolabs, Inc. (US), Reaction Biology (US), AAT Bioquest, Inc. (US), Pestka Biomedical Laboratories, Inc. (US) , Neuromics (US), BPS Bioscience, Inc. (US), BellBrook Labs (US), Profacgen (US), BMG LABTECH (Germany), Hanugen Theraputics (India), Altogen Labs (US), and BioAgilytix (US), among others in the market.
457
